Skip to main content
Log in

Rebound insomnia and newer hypnotics

  • Review
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The prescription of hypnotics, mostly benzodiazepines, continues at a high level. One problem with their use is rebound insomnia: upon discontinuation sleep worsens compared with pretreatment levels. Factors influencing rebound include the type of subject, the duration of action of the hypnotic, the dosage and perhaps duration of treatment. The detection of rebound requires both sleep-laboratory and clinical studies with night-by-night analyses of individual patient data. This review concentrates on the newer compounds, (quazepam and zolpidem) which act selectively on subtypes of benzodiazepine receptors or bind atypically (zopiclone). It concludes that present evidence, while limited, is consistent with claims of less rebound potential than older benzodiazepine hypnotics of equivalent duration of action. Nevertheless, further rigorous studies are essential before these claims can be totally accepted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adam K, Adamson L, Brezinova V, Hunter WM, Oswald I (1976) Nitrazepam: lastingly effective but trouble on withdrawal. BMJ 1:1558–1560

    Google Scholar 

  • Adam K, Oswald I, Shapiro C (1984) Effects of loprazolam and of triazolam on sleep and overnight urinary cortisol. Psychopharmacology 82:389–394

    Google Scholar 

  • Allen RP, Mendels J, Nevins DB, Chernik DA, Hoddes E (1987) Efficacy without tolerance or rebound insomnia for midazolam and temazepam after use for one to three months. J Clin Pharmacol 27:768–775

    Google Scholar 

  • Anderson AA (1987) Zopiclone and nitrazepam: a multicenter placebo controlled comparative study of efficacy and tolerance in insomniac patients in general practice. Sleep 10 [suppl 1]:54–62

    Google Scholar 

  • Ankier SI, Goa KL (1988) Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. Drugs 35:42–62

    Google Scholar 

  • Besset A, Tafti M, Barthouil P, Rossi P, Billiard M (1990) Effect of zolpidem 10 mg on sleep architecture and daytime psychomotor skills in poor sleepers. 4th Annual Meeting of the Association of Professional Sleep Societies, Minneapolis

  • Bixler EO, Kales A, Soldatos CR, Kales JD (1977) Flunitrazepam, an investigational hypnotic drug: sleep laboratory evaluations. J Clin Pharmacol 17:569–578

    Google Scholar 

  • Clark BG, Jue SG, Dawson GW, Ward A (1986) Loprazolam. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in insomnia. Drugs 31:500–516

    Google Scholar 

  • Costa E, Puia G, Vicini S (1991) Impact of current developments in molecular biology on the pharmacotherapy of anxiety disorders. In: Meltzer D, Nerozzi D (eds) Current practices and future developments in the pharmacotherapy of mental disorders. Elsevier

  • Curran HV, Schifano F, Lader M (1991) Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Psychopharmacology 103:83–90

    Google Scholar 

  • Dorian P, Sellers EM, Kaplan H, Hamilton C (1982) Evaluation of zopiclone physical dependence liability in normal volunteers. Int Pharmacopsychiatr 17 [suppl 2]:228–234

    Google Scholar 

  • Dunbar GC et al. (1989) Patterns of benzodiazepine use in Great Britain as measured by a general population survey. Br J Psychiatry 155:836–841

    Google Scholar 

  • Elie R, Prenay M, Le Morvan P, Bourgouin J (1990a) Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol 5 [suppl 2]:39–46

    Google Scholar 

  • Elie R, Lavoie G, Bourgouin J, Le Morvan P (1990b) Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal. Int Clin Psychopharmacol 5:279–286

    Google Scholar 

  • Emeriau JP, Descamps A, Dechelotte P, Poch B, Harribey B, Alla P, Colle M (1988) Zolpidem and flunitrazepam: a multicenter trial in elderly hospitalized patients. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 317–326

    Google Scholar 

  • Fleming JA, McClure DJ, Mayes C, Phillips R, Bourgouin J (1990) A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia. Int Clin Psychopharmacol 5 [suppl 2]:29–38

    Google Scholar 

  • Gaillot J, Le Roux Y, Houghton GW, Dreyfus JP (1987) Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. Sleep 10 [suppl 1]:7–21

    Google Scholar 

  • Goa KL, Heel RC (1986) Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 32:48–65

    Google Scholar 

  • Gillin JC, Spinweber CL, Johnson LC (1989) Rebound insomnia: A critical review. J Clin Psychopharmacol 9:161–172

    Google Scholar 

  • Godtlibsen OB, Dreyfus JF (1980) Effect of 7.5 mg zopiclone (27.267RP) on sleep pattern in normal subjects. Waking and Sleeping 4:319–325

    Google Scholar 

  • Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI (1987) Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. New Engl J Med 317:722–728

    Google Scholar 

  • Greenblatt DJ, Miller LG, Shader RI (1990) Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs. Am J Med 88 [suppl 3A]:18S-24S

    Google Scholar 

  • Guelfi JD (1990) Nouveaux psychotropes et cycles du sommeil. Ann Psychiatr 4:314–317

    Google Scholar 

  • Herrmann WM, Kubicki St, Wober W (1988) Zolpidem: a four-week pilot polysomnographic study in patients with chronic sleep disturbances. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 261–278

    Google Scholar 

  • Jovanovic UJ, Dreyfus JF (1982) Polygraphical sleep recordings in insomniac patients under zopiclone or nitrazepam. Int Pharmacopsychiatr 17 [suppl 2]:136–145

    Google Scholar 

  • Julou L, Blanchard JC, Dreyfus JP (1985) Pharmacological and clinical studies of cyclopyrrolones: zopiclone and suriclone. Pharmacol Biochem Behav 23:653–659

    Google Scholar 

  • Kales A (1990) Quazepam: hypnotic efficacy and side effects. Pharmacotherapy 10:1–12

    Google Scholar 

  • Kales A, Kales JD (1984) Evaluation and treatment of insomnia. Oxford University Press, Oxford

    Google Scholar 

  • Kales A, Bixler EO, Scharf M, Kales JD (1976) Sleep laboratory studies of flurazepam: a model for evaluating hypnotic drugs. Clin Pharmacol Ther 19:576–583

    Google Scholar 

  • Kales A, Scharf MB, Kales JD (1978) Rebound insomnia: a new clinical syndrome. Science 201:1039–1040

    Google Scholar 

  • Kales A, Scharf MB, Kales JD, Soldatos CR (1979) Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines. JAMA 241:1692–1695

    Google Scholar 

  • Kales A, Bixler EO, Soldatos CR (1982a) Dose-response studies of lormetazepam: efficacy, side effects, and rebound insomnia. J Clin Pharmacol 22:520–530

    Google Scholar 

  • Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby J, Kales JD (1982b) Quazepam and flurazepam: long-term use and extended withdrawal. Clin Pharmacol Ther 32:781–788

    Google Scholar 

  • Kales A, Soldatos CR, Bixler E, Goff PJ, Vela-Bueno A (1983a) Midazolam: dose-response studies of effectiveness and rebound insomnia. Pharmacology 26:138–149

    Google Scholar 

  • Kales A, Soldatos CR, Bixler EO, Kales JD (1983b) Rebound insomnia and rebound anxiety: a review. Pharmacology 24:121–137

    Google Scholar 

  • Kales A, Bixler EO, Soldatos CR, Jacoby JA, Kales JD (1986a) Lorazepam: effects on sleep and withdrawal phenomena. Pharmacology 32:121–130

    Google Scholar 

  • Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby J, Kales JD (1986b) Quazepam and temazepam: effects of short- and intermediate-term use and withdrawal. Clin Pharmacol Ther 39:345–352

    Google Scholar 

  • Kales A, Bixler EO, Vela-Bueno A, Soldatos CR, Niklaus DE, Manfredi RL (1986c) Comparison of short and long half-life benzodiazepine hypnotics: triazolam and quazepam. Clin Pharmacol Ther 40:378–386

    Google Scholar 

  • Kales A, Bixler EO, Vela-Bueno A, Soldatos CR, Manfredi RL (1987) Alprazolam: effects on sleep and withdrawal phenomena. J Clin Pharmacol 27:508–515

    Google Scholar 

  • Kales JD, Kales A, Soldatos CR (1985) Quazepam: sleep laboratory studies of effectiveness and withdrawal. Neuropharmacology 8:S55–62

    Google Scholar 

  • Kurtz D, Baas V, Rumbach L (1990) Effects on nocturnal sleep and daytime vigilance of zolpidem 10 mg administered during 14 nights to poor sleepers. Abstract of 1st Conference — Congress of European Sleep Research Society Strasbourg

  • Lader M, Frcka G (1987) Subjective effects during administration and on discontinuation of zopiclone and temazepam in normal subjects. Pharmacopsychiatry 20:67–71

    Google Scholar 

  • Lader M, Lawson C (1987) Sleep studies and rebound insomnia: methodological problems, laboratory findings, and clinical implications. Clin Neuropharmacology 10:291–312

    Google Scholar 

  • Lamphere J, Roehrs T, Vogel G, Koshorek G, Fortier J, Roth T (1990) The chronic efficacy of midazolam. Int Clin Psychopharmacol 5:31–39

    Google Scholar 

  • Langer SZ, Arbilla S, Scatton B, Niddam R, Dubois A (1988) Receptors involved in the mechanism of action of zolpidem. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 55–70

    Google Scholar 

  • Langley MS, Clissold SP (1988) Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. Drugs 35:104–122

    Google Scholar 

  • Langtry HD, Benfield P (1990) Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 40:291–313

    Google Scholar 

  • Lorizio A, Terzano MG, Parrino L, Cesana BM, Priorie P (1990) Zolpidem: a double-blind comparison of the hypnotic activity and safety of a 10-mg versus 20-mg dose. Curr Ther Res 47:889–898

    Google Scholar 

  • Maggioni M, Frattola L (1988) Double-blind controlled study of the efficacy and safety of zolpidem versus flunitrazepam. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 386–387

    Google Scholar 

  • Mamelak M, Csima A, Price V (1982) Effects of zopiclone on the sleep of chronic insomniacs. Int Pharmacopsychiatr 17 [suppl 2]:156–164

    Google Scholar 

  • Mamelak M, Csima A, Buck L, Price V (1989) A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharmacol 9:260–267

    Google Scholar 

  • Mamelak M, Csima A, Price V (1990) The effects of a single night's dosing with triazolam on sleep the following night. J Clin Pharmacol 30:549–555

    Google Scholar 

  • McClure DJ, Walsh J, Chang H, Olah A, Wilson R, Pecknold JC (1988) Comparison of lorazepam and flurazepam as hypnotic agents in chronic insomniacs. J Clin Pharmacol 28:52–63

    Google Scholar 

  • Mattmann P, Loepfe M, Scheitlin T, Schmidlin D, Gerne M, Strauch I, Lehmann D, Borbély AA (1982) Day-time residual effects and motor activity after three benzodiazepine hypnotics. Drug Res 32[I]:461–465

    Google Scholar 

  • Mellinger GD, Balter MB, Uhlenhuth EH (1985) Insomnia and its treatment. Arch Gen Psychiatry 42:225–232

    Google Scholar 

  • Mello de Paula AJ (1983) Comparative study of zopiclone and pentobarbitone as hypnotics. Pharmacology 27 [suppl 2]:188–195

    Google Scholar 

  • Mereu G, Carcangiu G, Concas A, Passino N, Biggio G (1990) Reduction of reticulata neuronal activity by zolpidem and alpidem, two imidazopyridines with high affinity for type I benzodiazepine receptors. Eur J Pharmacol 179:339–346

    Google Scholar 

  • Merlotti L, Roehrs T, Zorick FJ, Roth T (1991) Rebound insomnia: Duration of use and individual differences. J Clin Psychopharmacol 11:368–373

    Google Scholar 

  • Monti JM (1989) Effect of zolpidem on sleep in insomniac patients. Eur J Clin Pharmacol 36:461–466

    Google Scholar 

  • Morgan K (1990) Hypnotics in the elderly. What cause for concern? Drugs 10:688–696

    Google Scholar 

  • Morgan K, Tomeny M (1988) Benzodiazepine withdrawal and rebound insomnia. Acta Psychiatr Scand 78:297–298

    Google Scholar 

  • Morgan K, Dallsoo H, Ebrahim S, Arie T, Fentem PH (1988) Prevalence, frequency, and duration of hypnotic drug use among the elderly living at home. BMJ 296:601–602

    Google Scholar 

  • Mouret J, Ruel D, Maillard P, Bianchi M (1990) Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone. Int Clin Psychopharmacol 5:47–55

    Google Scholar 

  • Oswald I, Adam K, Borrow S, Idzikowski C (1979) The effects of two hypnotics on sleep, subjective feelings and skilled performance. In: Pussouant O, Oswald I (eds) Pharmacology of the states of alertness. Pergamon Press, Oxford, pp 51–63

    Google Scholar 

  • Oswald I, French C, Adam K, Gilham J (1982) Benzodiazepine hypnotics remain effective for 24 weeks. BMJ 284:860–863

    Google Scholar 

  • Pecknold J, Wilson R, Le Morvan P (1990) Long term efficacy and withdrawal of zopiclone: a sleep laboratory study. Int Clin Psychopharmacol 5 [suppl 2]:57–67

    Google Scholar 

  • Prinz PN, Vitiello MV, Raskin MA, Thorpy MJ (1990) Geriatrics: sleep disorders and aging. New Engl J Med:520–526

  • Quadens OP, Hoffman G, Buytaert G (1982) Effects of zopiclone as compared to flurazepam on sleep in women over 40 years of age. Int Pharmacopsychiatr 17 [suppl 2]:146–155

    Google Scholar 

  • Roehrs T, Zorick F, Wittig R, Roth T (1986) Dose determinants of rebound insomnia. Br J Clin Pharmacol 22:143–147

    Google Scholar 

  • Roehrs T, Vogel G, Roth R (1990) Rebound insomnia: its determinants and significance. Am J Med 88 [suppl 3A]:395–425

    Google Scholar 

  • Roth T, Kramer M, Roehrs T (1977) The consistency of sleep measures. In: Proceedings of the 3rd European Congress on Sleep Research, Montpellier. Karger, Basel, pp 286–288

    Google Scholar 

  • Sauvanet JP, Maarek L, Roger M, Renaudin J, Louvel E, Orofiamma B (1988) Open long-term trials with zolpidem in insomnia. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 339–349

    Google Scholar 

  • Scharf MB, Sachais BA, Mayleben DW, Fletcher K, Jennings SW (1990) A polysomnographic comparison of temazepam 15 and 30 mg with triazolam 0.125 and 0.25 mg in chronic insomnia. Curr Ther Res 18:555–567

    Google Scholar 

  • Scharf MB, Mayleben DW, Kaffeman M, Krall R, Ochs R (1991) Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 52:2:77–83

    Google Scholar 

  • Schlich D, L'Heritier C, Coquelin JP, Attali P (1991) Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 19:271–279

    Google Scholar 

  • Schneider-Helmert D (1988) Why low-dose benzodiazepine-dependent insomniacs can't escape their sleeping pills. Acta Psychiatr Scand 78:706–711

    Google Scholar 

  • Shaw SH (1988) Double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, p 389

    Google Scholar 

  • Spinweber CL, Johnson LC (1982) Effects of triazolam (0.5 mg) on sleep, performance, memory, and arousal threshold. Psychopharmacology 76:5–12

    Google Scholar 

  • Tham TCK, Brown H, Taggart HMcA (1989) Temazepam withdrawal in elderly hospitalized patients: a double blind randomised trial comparing abrupt versus gradual withdrawal. Int J Med Sci, 12:294–296

    Google Scholar 

  • Tiberge M, Calvet U, Khayi N, Delahaye C, Arbus L (1988) Comparaison des effets de la zopiclone et du triazolam sur le sommeil du sujet sain. L'Encéphale 14:319–324

    Google Scholar 

  • Trifiletti RR, Snyder SH (1984) Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors. Mol Pharmacol 26:458–469

    Google Scholar 

  • US Department of Health Education and Welfare (1977) Guidelines for the clinical evaluation of hypnotic drugs. US Government Printing Office, Washington DC

    Google Scholar 

  • Vogel G, Scharf M, Walsh J, Roth T (1989) Effects of chronically administered zolpidem on the sleep of healthy insomniacs. Sleep Res 18:80

    Google Scholar 

  • Wheatley D (1988) Zolpidem and placebo: a study in general practice in patients suffering from insomnia. In: Sauvanet JP, Lander SZ, Morselli PL (eds) Imidazopyridines in sleep disorders. Raven Press, New York, pp 305–316

    Google Scholar 

  • Wickstrom E, Barbo SE, Dreyfus JF, Jerke D, Kleiven R, Slattbrekk R, Stray Tonnesen JN (1983) A comparative study of zopiclone and flunitrazepam in insomniacs seen by general practitioners. Pharmacology 27 [suppl 2]:165–172

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lader, M. Rebound insomnia and newer hypnotics. Psychopharmacology 108, 248–255 (1992). https://doi.org/10.1007/BF02245108

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02245108

Key words

Navigation